Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
132 hedge funds and large institutions have $474M invested in Merrimack Pharmaceuticals, Inc. in 2014 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 41 increasing their positions, 32 reducing their positions, and 17 closing their positions.
65% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 17
62% more call options, than puts
Call options by funds: $5.42M | Put options by funds: $3.35M
28% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 32
16% more capital invested
Capital invested by funds: $407M → $474M (+$67.1M)
9% more funds holding
Funds holding: 121 → 132 (+11)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$10.4M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$4.19M |
| 3 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$2.87M |
| 4 |
Jane Street
New York
|
+$2.19M |
| 5 |
ACM
Alpha Capital Management
Austin,
Texas
|
+$1.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$35.3M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$5.58M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$4.45M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3.71M |
| 5 |
Goldman Sachs
New York
|
-$2.37M |
MACK Hedge Fund Activity: Q3 2014 in Review
132 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q3 2014, worth a combined $474M — up 16% from $407M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new MACK positions and 17 closed out — a net gain of 11 holders — while 41 added to existing stakes and 32 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $10.4M. The largest seller was Jennison Associates, exiting entirely with an estimated $35.3M sold.
- 132 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q3 2014, up from 121 in Q2 2014.
- Funds reported $474M of Merrimack Pharmaceuticals, Inc. stock for Q3 2014, up 16% quarter-over-quarter.
- 28 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q3 2014 and 17 closed out, a net change of +11 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q3 2014 was Consonance Capital Management, an estimated $10.4M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q3 2014 was Jennison Associates, an estimated $35.3M sold.
Based on aggregated 13F filings for Q3 2014.